- What's Tisch?
- Stem Cell Trial
- Get Involved
The Tisch MS Research Center presented two posters at the International Society for Stem Cell Research (ISSCR) 12th Annual Meeting last week based on the following study.
Safety and Dosing of Autologous Neural Progenitors Injected Intrathecally in Multiple Sclerosis Patients: Results of a Pilot Study
Saud A. Sadiq, and Violaine K. Harris
Summary: Six patients with progressive forms of MS and one with spinal cord atrophy were given between 2 and 5 injections via spinal tap of their own mesenchymal stem cell-derived neural progenitors (MSC-NPs) spaced an average of 5 months apart as part of an exploratory pilot study. There were no significant short-term or long-term adverse events, and 4 out of 6 MS patients showed a measureable clinical improvement as a result of the MSC-NP treatments. Based on these initial findings, it was determined that MSC-NPs administered by intrathecal injection every 3 months would be safe and feasible.
For more info on the ISSCR and this important event, visit: www.isscr.org
521 West 57th Street
New York, NY 10019
Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.